<div id="readability-page-1"><div>RNS Number : 0208I Hikma Pharmaceuticals Plc 12 June 2026 TR-1: Standard form for notification of major holdingsLONDON, 12 June 2026 - Hikma Pharmaceuticals PLC (LEI:549300BNS685UXH4JI75) announces as follows:<div><table><tbody><tr><td colspan="7">NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i</td></tr><tr><td colspan="7"></td></tr><tr><td colspan="3">1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:</td><td colspan="4">Hikma Pharmaceuticals Public Limited Company</td></tr><tr><td colspan="7">1b. Please indicate if the issuer is a non-UK issuer (please mark with an &#34;X&#34; if appropriate)</td></tr><tr><td colspan="6">Non-UK issuer</td><td></td></tr><tr><td colspan="7">2. Reason for the notification (please mark the appropriate box or boxes with an &#34;X&#34;)</td></tr><tr><td colspan="6">An acquisition or disposal of voting rights</td><td>X</td></tr><tr><td colspan="6">An acquisition or disposal of financial instruments</td><td></td></tr><tr><td colspan="6">An event changing the breakdown of voting rights</td><td></td></tr><tr><td colspan="6">Other (please specify) iii:</td><td></td></tr><tr><td colspan="7">3. Details of person subject to the notification obligationiv</td></tr><tr><td colspan="3">Name</td><td colspan="4">Wellington Management Group LLP</td></tr><tr><td colspan="3">City and country of registered office (if applicable)</td><td colspan="4">Boston, United States</td></tr><tr><td colspan="7">4. Full name of shareholder(s) (if different from 3.) v</td></tr><tr><td colspan="3">Name</td><td colspan="4">VIDACOS NOMINEES LIMITEDState Street Nominees LimitedROY Nominees LimitedNortrust Nominees LimitedMellon Nominees (UK) Ltd.JP Morgan Chase Nominees LimitedHSBC Global Custody Nominee (UK) LimitedGoldman Sachs InternationalEuroclear Nominees LimitedBBH ISL NOMINEES LTD</td></tr><tr><td colspan="3">City and country of registered office (if applicable)</td><td colspan="4"></td></tr><tr><td colspan="3">5. Date on which the threshold was crossed or reachedvi:</td><td colspan="4">09/06/2026</td></tr><tr><td colspan="3">6. Date on which issuer notified (DD/MM/YYYY):</td><td colspan="4">11/06/2026</td></tr><tr><td colspan="7">7. Total positions of person(s) subject to the notification obligation</td></tr><tr><td></td><td>% of voting rights attached to shares (total of 8.A)</td><td colspan="2">% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)</td><td>Total of both in % (8.A + 8.B)</td><td colspan="2">Total number of voting rights held in issuervii</td></tr><tr><td>Resulting situation on the date on which threshold was crossed or reached</td><td>4.990000</td><td colspan="2">0.010000</td><td>5.000000</td><td colspan="2">10700713</td></tr><tr><td>Position of previous notification (ifapplicable)</td><td></td><td colspan="2"></td><td></td><td colspan="2"></td></tr></tbody></table></div><div><table><tbody><tr><td colspan="10">8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii</td></tr><tr><td colspan="10">A: Voting rights attached to shares</td></tr><tr><td colspan="2" rowspan="2">Class/type ofsharesISIN code (if possible)</td><td colspan="5">Number of voting rightsix</td><td colspan="3">% of voting rights</td></tr><tr><td colspan="2">Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)</td><td colspan="3">Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)</td><td colspan="2">Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)</td><td>Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)</td></tr><tr><td colspan="2">GB00B0LCW083</td><td colspan="2"></td><td colspan="3">10683885</td><td colspan="2"></td><td>4.990000</td></tr><tr><td colspan="2"></td><td colspan="2"></td><td colspan="3"></td><td colspan="2"></td><td></td></tr><tr><td colspan="2">SUBTOTAL 8. A</td><td colspan="5">10683885</td><td colspan="3">4.990000%</td></tr><tr><td colspan="10"></td></tr><tr><td colspan="10">B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))</td></tr><tr><td colspan="2">Type of financial instrument</td><td>Expirationdatex</td><td colspan="3">Exercise/Conversion Periodxi</td><td colspan="3">Number of voting rights that may be acquired if the instrument isexercised/converted.</td><td>% of voting rights</td></tr><tr><td colspan="2"></td><td></td><td colspan="3">SUBTOTAL 8. B 1</td><td colspan="3"></td><td></td></tr><tr><td colspan="10"></td></tr><tr><td colspan="10">B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))</td></tr><tr><td>Type of financial instrument</td><td colspan="2">Expirationdatex</td><td colspan="2">Exercise/Conversion Period xi</td><td colspan="3">Physical or cashsettlementxii</td><td>Number of voting rights</td><td>% of voting rights</td></tr><tr><td>Equity swap</td><td colspan="2">15/05/2033</td><td colspan="2">15/05/2033</td><td colspan="3">Cash</td><td>16828</td><td>0.010000</td></tr><tr><td></td><td colspan="2"></td><td colspan="2"></td><td colspan="3">SUBTOTAL 8.B.2</td><td>16828</td><td>0.010000%</td></tr></tbody></table></div><div><table><tbody><tr><td colspan="8">9. Information in relation to the person subject to the notification obligation (please mark theapplicable box with an &#34;X&#34;)</td><td></td></tr><tr><td colspan="7">Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii</td><td></td><td></td></tr><tr><td colspan="7">Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)</td><td>X</td><td></td></tr><tr><td colspan="8"></td><td></td></tr><tr><td>Ultimate controlling person</td><td colspan="2">Name of controlled undertaking</td><td>% of voting rights if it equals or is higher than the notifiable threshold</td><td>% of voting rights through financial instruments if it equals or is higher than the notifiable threshold</td><td colspan="3">Total of both if it equals or is higher than the notifiable threshold</td></tr><tr><td>Wellington Management Group LLP (Chain 1)</td><td colspan="2">Wellington Group Holdings LLP</td><td></td><td></td><td colspan="3">5.000000%</td></tr><tr><td>Wellington Management Group LLP (Chain 1)</td><td colspan="2">Wellington Investment Advisors Holdings LLP</td><td></td><td></td><td colspan="3">5.000000%</td></tr><tr><td>Wellington Management Group LLP (Chain 1)</td><td colspan="2">Wellington Management Global Holdings, Ltd.</td><td></td><td></td><td colspan="3"></td></tr><tr><td>Wellington Management Group LLP (Chain 1)</td><td colspan="2">Wellington Management International Ltd</td><td></td><td></td><td colspan="3"></td></tr><tr><td>Wellington Management Group LLP (Chain 2)</td><td colspan="2">Wellington Group Holdings LLP</td><td></td><td></td><td colspan="3">5.000000%</td></tr><tr><td>Wellington Management Group LLP (Chain 2)</td><td colspan="2">Wellington Investment Advisors Holdings LLP</td><td></td><td></td><td colspan="3">5.000000%</td></tr><tr><td>Wellington Management Group LLP (Chain 2)</td><td colspan="2">Wellington Management Company LLP</td><td></td><td></td><td colspan="3"></td></tr><tr><td colspan="8"></td><td></td></tr><tr><td colspan="8">10. In case of proxy voting, please identify:</td><td></td></tr><tr><td colspan="3">Name of the proxy holder</td><td colspan="5"></td><td></td></tr><tr><td colspan="3">The number and % of voting rights held</td><td colspan="5"></td><td></td></tr><tr><td colspan="3">The date until which the voting rights will be held</td><td colspan="5"></td><td></td></tr><tr><td colspan="8"></td><td></td></tr><tr><td colspan="8">11. Additional informationxvi</td><td></td></tr><tr><td colspan="8">Wellington Management Company LLP is an investment management entity that manages the assets of certain funds and/or managed accounts.Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.Wellington Management International Ltd is an investment management entity that manages the assets of certain funds and/or managed accounts.Wellington Management International Ltd is a direct controlled undertaking of Wellington Management Global Holdings, Ltd., which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP, which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.</td><td></td></tr></tbody></table></div><div><table><tbody><tr><td>Place of completion</td><td>London, UK</td></tr><tr><td>Date of completion</td><td>11-Jun-2026</td></tr></tbody></table></div>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END HOLUAUKRNOUNAAR</div></div>

Hikma Pharmaceuticals announced that Wellington Management Group LLP crossed the 5% voting rights threshold on June 9, 2026. The notification details holdings through various nominee accounts and financial instruments, including equity swaps. The ultimate controlling entity is identified as Wellington Management Group LLP.

London Stock Exchange

Hikma Pharmaceuticals Plc

State Street

Northern Trust

JPMorgan Chase

HSBC Holdings Plc

Goldman Sachs

State Street® US Equity Premium Inc ETF

Northern Trust Pref Share NTRSO 4.7 Perp 01/01/25 E

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

HSBC 5xShortSG241213

HSBC HOLDINGS

HSBC

GS Hldg R

REG - Hikma Pharmaceutical - Holding(s) in Company